- Home
- EDUC vs AIM Comparison
EDUC vs AIM Comparison
Compare EDUC & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- AIM
- Stock Information
- Founded
- EDUC 1965
- AIM 1966
- Country
- EDUC United States
- AIM United States
- Employees
- EDUC N/A
- AIM N/A
- Industry
- EDUC Consumer Specialties
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDUC Consumer Discretionary
- AIM Health Care
- Exchange
- EDUC Nasdaq
- AIM Nasdaq
- Market Cap
- EDUC 16.6M
- AIM 15.9M
- IPO Year
- EDUC N/A
- AIM N/A
- Fundamental
- Price
- EDUC $1.82
- AIM $0.21
- Analyst Decision
- EDUC
- AIM Strong Buy
- Analyst Count
- EDUC 0
- AIM 2
- Target Price
- EDUC N/A
- AIM $3.00
- AVG Volume (30 Days)
- EDUC 6.8K
- AIM 688.6K
- Earning Date
- EDUC 01-09-2025
- AIM 11-15-2024
- Dividend Yield
- EDUC N/A
- AIM N/A
- EPS Growth
- EDUC N/A
- AIM N/A
- EPS
- EDUC N/A
- AIM N/A
- Revenue
- EDUC $42,415,800.00
- AIM $190,000.00
- Revenue This Year
- EDUC N/A
- AIM N/A
- Revenue Next Year
- EDUC N/A
- AIM $1,086.80
- P/E Ratio
- EDUC N/A
- AIM N/A
- Revenue Growth
- EDUC N/A
- AIM N/A
- 52 Week Low
- EDUC $0.80
- AIM $0.16
- 52 Week High
- EDUC $2.95
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- EDUC 30.96
- AIM 40.08
- Support Level
- EDUC $1.78
- AIM $0.16
- Resistance Level
- EDUC $2.00
- AIM $0.22
- Average True Range (ATR)
- EDUC 0.10
- AIM 0.03
- MACD
- EDUC -0.01
- AIM -0.00
- Stochastic Oscillator
- EDUC 12.12
- AIM 45.64
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.